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Abstract
Introduction
The incidence of cervical cancer in Appalachia exceeds 
the national rate; rural Appalachian women are at espe-
cially high risk. We assessed the attitudes and practices 
related to human papillomavirus vaccination among pro-
viders in primary care practices in a contiguous 5-county 
area of Appalachian Pennsylvania.
Methods
In December 2006 and May 2007, all family medicine, 
pediatric, and gynecology practices (n = 65) in the study 
area were surveyed by 2 faxed survey instruments.
Results
Of the 65 practices, 55 completed the first survey instru-
ment. Of these 55, 44 offered the vaccine to their patients. 
Forty  of  the  44  practices  offered  it  to  girls  and  women 
aged 9 to 26 years, and 11 were willing to accept referrals 
from other practices for vaccination. The average reported 
charge for each of the 3 required injections was $150. Of 
the 55 practices that responded to the first survey instru-
ment, 49 responded to the second survey instrument, 46 of 
which recommended the vaccine to their patients.
Conclusions
The prevalence of offering the vaccine against human 
papillomavirus  was  high  in  this  area  of  Appalachian 
Pennsylvania. Future interventions may focus on commu-
nity education because the vaccine is available from most 
providers.
Introduction
Human  papillomavirus  (HPV),  which  causes  genital 
warts and cervical cancer, is the most common sexually 
transmitted infection in the United States; an estimated 
6.2 million people are infected every year (1). The preva-
lence of HPV infection increases with each year of age, 
from 14 to 24 years, followed by a gradual decline through 
age 59 (2).
In June 2006, the US Food and Drug Administration 
licensed  HPV  quadrivalent  vaccine  for  use  in  girls  and 
women aged 9 to 26 years as a vaccine against HPV types 
6, 11, 16, and 18, which collectively account for 70% of 
cervical cancers and 90% of genital warts (1). Pediatricians 
(3) and family physicians (4) reported that they would be 
more  likely  to  administer  an  approved  HPV  vaccine  to 
girls than to boys and to older children than to younger 
children (5). A systematic, theory-based review of 28 stud-
ies conducted before the HPV vaccine was licensed found 
that parents reacted positively to the possibility of vac-
cinating their daughters against HPV, especially if they 
thought infection was likely and the vaccine was effective 
and recommended by a physician (6).
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Cervical cancer incidence and mortality are higher in 
Appalachia than in the United States as a whole (7,8). 
ACTION Health is a nonprofit community organization 
that  uses  evidence-based  initiatives  to  improve  health 
and eliminate health disparities among residents of a con-
tiguous  5-county  (Columbia,  Montour,  Northumberland, 
Snyder,  and  Union)  area  in  Appalachian  Pennsylvania 
(Figure). The 5 counties of ACTION Health are largely 
rural (52%) and have a median population of 43,387 (range, 
17,934-91,654), which is predominantly (96%) white (9). 
Women and girls aged 15 to 24 make up a median 8.8% 
(range, 5.3%-12.0%) of the population in these counties, 
and  a  median  13.9%  (range,  9.6%-14.8%)  of  the  county 
population is eligible for medical assistance (10).
From 2003 through 2005, 45 cases of invasive cervical 
cancer  were  reported  in  the  5-county  ACTION  Health 
area. According to the Pennsylvania Cancer Registry, 31 
cases were expected during this period (11). Also during 
this period, 12% of women aged 18 to 64 were uninsured 
and 17% did not have a regular physician (11,12).
Because of the apparent increased risk of cervical cancer 
in this area, these women may benefit from HPV vaccina-
tion.  We  surveyed  primary  care  practices  to  determine 
HPV vaccine–related practices and recommendations in 
the ACTION Health area. The study was the first of its 
kind in the ACTION Health service area and the northern 
Appalachian region overall.
Methods
In December 2006, ACTION Health conducted an ini-
tial survey of all primary care practices (n = 65), defined 
as  family  medicine,  pediatric,  and  gynecology  practices, 
including  public  clinics  and  university  health  centers, 
in the ACTION Health area. We identified practices by 
reviewing telephone listings and hospital Web sites and 
by  querying  coalition  members.  We  initially  contacted 
practices by telephone, and then we faxed them a 1-page 
survey (Appendix) that took less than 5 minutes to com-
plete. We asked the person in the practice who was most 
knowledgeable  about  the  HPV  vaccine  to  complete  and 
return the instrument.
In May 2007, a second survey was faxed to the people 
who returned the initial instrument (n = 55) because we 
wanted  to  develop  a  strategy  for  a  future  intervention 
(Appendix).  The  second  instrument  took  approximately 
5  minutes  to  complete.  We  did  not  collect  data  on  the 
training or position of the person who completed either 
instrument. We calculated prevalence estimates and 95% 
confidence intervals (CIs) for all results. The institutional 
review board of The Pennsylvania State University deter-
mined this study to be exempt from review.
Results
Of the 65 primary care practices, 55 returned a com-
pleted initial instrument (response rate, 85%). Of these, 
44 (80%; 95% CI, 69%-91%) offered the vaccine to their 
patients. Fifteen (27%; 95% CI, 16%-39%) practices that 
offered the vaccine reported at least 1 concern about the 
vaccine; concerns included cost and insurance coverage (n 
= 9), newness of the vaccine (n = 7), that the recommended 
age was too young (n = 4), and not knowing what type of 
physician should administer the vaccine (n = 1). Of the 44 
practices that offered the vaccine, 40 (91%) offered it to 
all girls and women aged 9 to 26 years; 11 (25%) reported 
that they were willing to take referrals of other practices’ 
patients  for  vaccination,  although  most  reported  that  a 
new patient must first receive a comprehensive exam and 
related care (for example, Papanicolaou test). The average 
reported charge for each of the 3 required injections was 
$150, which included the cost of the office visit. Thirty 
(68%) respondents reported that they were willing to post 
Figure. ACTION Health area: Columbia, Montour, Northumberland, Snyder, 
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flyers on HPV educational programs. Of the 11 practices 
that did not offer the vaccine, 9 (82%) expressed interest 
in offering it in the near future, and 2 (18%) requested 
additional information. Reasons that the 11 practices gave 
for not currently offering the vaccine included planning to 
offer the vaccine in the near future (n = 3), more research 
and information needed (n = 2), vaccine too new (n = 2), not 
enough patient interest (n = 1), physician at the practice 
had been ill and had no information (n = 1), vaccine should 
be given by the patient’s gynecologist (n = 1), and needed 
corporate approval to offer the vaccine (n = 1).
Of the 55 practices that responded to the initial instru-
ment, 49 (89%) completed the second instrument. Of these, 
46 (94%; 95% CI, 87%-100%) reported that they recom-
mended the vaccine to their patients, and 44 (90%; 95% 
CI, 81%-98%) reported that patients were requesting the 
vaccine for themselves or their daughters. Eighteen (39%) 
practices reported mostly vaccinating only those younger 
than 18 years, 10 (22%) reported mostly vaccinating only 
those aged 18 to 26, 11 (24%) reported vaccinating both 
age groups, and 7 (15%) did not report a specific age group. 
Several practices reported that they did not vaccinate girls 
in certain age groups: rarely under 11 (n = 1), not under 12 
(n = 1), not under 13 (n = 1), not under 15 (n = 1), and not 
under 16 (n = 2). In some cases, practices indicated that 
the approved age was too young, and in other cases they 
indicated they had no requests for the vaccine in those age 
groups. The 46 practices that recommended the vaccine 
gave an average of 39 (range, 33-45) first doses each week; 
41  practices  (89%)  reported  that  patients  received  the 
second and third doses. Six (13%) providers who recom-
mended the vaccine were willing to speak at a future edu-
cational program. Practices that recommended the vaccine 
reported concerns, including cost (n = 2; 4%) and limited 
patient interest because the vaccine was relatively new (n 
= 1; 2%). Of the 3 practices that did not recommend the 
vaccine, 2 were concerned that the recommended age was 
too young, and 1 reported a concern about the vaccine’s 
safety and effectiveness.
Discussion
We  found  that  the  HPV  vaccine  is  being  offered  to 
patients in the approved age range, 9 to 26 years, in a 5-
county region of Appalachian Pennsylvania. Most practices 
that did not currently offer the vaccine intended to offer 
it in the future. In addition, most practices were willing 
to provide the vaccine to patients of other practices and 
participate in educational programs. Barriers to vaccina-
tion included the cost of the vaccine, especially for women 
aged 18 to 26 years, an age group that is not covered by 
the Vaccines for Children program. The belief among some 
providers that the recommended age is too low and that 
the vaccine promotes sexual activity among young women 
may also restrict access to the vaccine. One family health 
practice that did not offer the vaccine at the time of the 
initial survey (“We are doing our own research and look-
ing to order vaccine soon.”) reported on second survey that 
they were offering the vaccine but not to young girls (“[The 
vaccine] is not given to the extremely young. We are wait-
ing for the vaccine to prove effective and safe. I don’t want 
patients to feel falsely safe and free to sleep around.”).
These findings can guide future community-based ini-
tiatives  to  increase  vaccination.  Barriers  to  vaccination, 
including cost and health insurance coverage, should be 
addressed in future initiatives. Other barriers have previ-
ously  been  reported,  including  lack  of  knowledge  about 
HPV transmission and associated risks for cervical cancer 
and  other  genital  diseases,  parental  concerns  about  the 
vaccine and vaccinating minors against sexually transmit-
ted infections, lack of knowledge about financial assistance 
programs, challenges related to health care–seeking behav-
ior of young women, and barriers specific to HPV infection 
(eg, protection against only certain types of HPV) (13).
Few evidence-based interventions to increase vaccination 
have been reported. A randomized study conducted before 
the  HPV  vaccine  was  licensed  found  that  parents  who 
received an HPV information sheet had higher mean scores 
on HPV knowledge than did parents who did not receive 
the information (13). However, the groups did not differ in 
terms of vaccine acceptability (13). Among women aged 18 
to 30, knowledge, personal beliefs about vaccination, belief 
that  others  would  approve  of  vaccination,  and  a  higher 
number  of  sexual  partners  were  significantly  associated 
with intention to vaccinate (3). A study of women aged 18 
to 25 found that those who had had vaginal sex in the past 
12 months were 4 times as likely to report acceptance of 
vaccination (14). In addition, those who had ever had a sex-
ually transmitted infection or an abnormal Papanicolaou 
test were also more likely to indicate acceptance.
Limitations to this study must be acknowledged. The 
sample  was  drawn  from  a  specific  geographic  area, 
thus  limiting  the  generalizabilty  of  the  results.  Several   VOLUME 6: NO. 2
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factors may have limited the validity of the results. First, 
the study collected data that were self-reported and not 
verified  by  direct  observation  or  medical  record  review. 
The  study  also  used  2  instruments  that  had  not  been 
validated previously. Instruments that had been validated 
in previous studies would have been preferable, but none 
was known to the investigators as the study was being 
planned. Two surveys of health care providers have since 
been reported (15,16).
The  study  also  has  numerous  strengths.  First,  the 
response rate was high, which may be partially because 
the survey was brief, was conducted by a local organiza-
tion, and focused on a timely topic. Second, the survey 
was conducted in Appalachia, a region that has cervical 
cancer  health  disparities.  Third,  the  study  was  partici-
patory  and  initiated  communication  between  ACTION 
Health and local primary care practices. Future partner-
ships may develop from this initial communication, which 
could  expand  ACTION  Health’s  network  of  health  care 
affiliates for cancer prevention and control. Finally, the 
study  design  was  community-based,  and  results  can  be 
used to facilitate future interventions in the specific area 
of ACTION Health.
We  conclude  that  most  practices  in  this  area  of 
Appalachian Pennsylvania recommend the HPV vaccine 
or provide it if patients request it. Future community edu-
cation interventions should target women and girls in the 
appropriate age range to increase their knowledge of cervi-
cal cancer and the risks and benefits of HPV vaccination.
Acknowledgments
This  study  received  partial  funding  from  ACTION 
Health and the National Cancer Institute (U01 CA114622: 
The Appalachia Community Cancer Network).
Author Information
Corresponding Author: Eugene J. Lengerich, VMD, MS, 
Professor,  Department  of  Public  Health  Sciences,  The 
Pennsylvania  State  University,  PO  Box  855,  Mailstop 
A210, 600 Centerview Dr, Ste 2200, Hershey, PA 17033-
0855.  Telephone:  717-531-7178.  E-mail:  elengerich@psu.
edu.
Author  Affiliations:  Nicole  L.  Huey,  Allison  D.  Clark, 
ACTION  Health  Cancer  Task  Force,  ACTION  Health, 
Danville,  Pennsylvania;  Brenda  C.  Kluhsman,  The 
Pennsylvania State University, Hershey, Pennsylvania.
References
 1.  Centers for Disease Control and Prevention. Sexually 
transmitted  diseases:  HPV  vaccine  information  for 
young  women.  http://www.cdc.gov/std/hpv/STDFact-
HPV-vaccine.htm. Accessed October 9, 2007.
 2.  Dunne  EF,  Unger  ER,  Sternberg  M,  McQuillan  G, 
Swan DC, Patel SS, et al. Prevalence of HPV infec-
tion  among  females  in  the  United  States.  JAMA 
2007;297(8):813-9.
 3.  Kahn  JA,  Rosenthal  SL,  Hamann  T,  Bernstein  DI. 
Attitudes  about  human  papillomavirus  vaccine  in 
young women. Int J STD AIDS 2003;14(5):300-6.
 4.  Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, 
Huang B, Lan D, et al. Attitudes about human papil-
lomavirus vaccine among family physicians. J Pediatr 
Adolesc Gynecol 2005;18(6):391-8.
 5.  Daley MF, Liddon N, Crane LA, Beaty BL, Barrow 
J, Babbel C, et al. A national survey of pediatrician 
knowledge and attitudes regarding human papilloma-
virus vaccination. Pediatrics 2006;118(6):2280-9.
 6.  Brewer NT, Fazekas KI. Predictors of HPV vaccine 
acceptability:  a  theory-informed,  systematic  review. 
Prev Med 2007;45(2-3):107-14.
 7.  Freeman  HP,  Wingrove  BK.  Excess  cervical  cancer 
mortality: a marker for low access to health care in 
poor  communities.  Rockville  (MD):  National  Cancer 
Institute,  National  Institutes  of  Health;  2005.  NIH 
publication no. 05-5282.
 8.  Lengerich  EJ,  Tucker  T,  Powell  RK,  Colsher  P, 
Lehman  E,  Ward  AJ,  et  al.  Cancer  incidence  in 
Kentucky, Pennsylvania, and West Virginia: dispari-
ties in Appalachia. J Rural Health 2005:21(1);39-47.
 9.  US  Census  Bureau.  State  and  county  quick  facts. 
http://quickfacts.census.gov/.  Accessed  August  31, 
2007.
10. Pennsylvania  Department  of  Health.  2006  county 
health  profiles.  http://www.dsf.health.state.pa.us/
health/cwp/view.asp?a=175&Q=246515.  Accessed 
December 10, 2008.
11. Pennsylvania  Department  of  Health.  EpiQMS:  epi-
demiologic  query  and  mapping  system.  http://app2.
health.state.pa.us/epiqms/. Accessed August 31, 2007.VOLUME 6: NO. 2
APRIL 2009
  www.cdc.gov/pcd/issues/2009/apr/08_0128.htm • Centers for Disease Control and Prevention  
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.
12. National  Cancer  Institute’s  Cancer  Information 
Service.  Clusters  in  need  of  cervical  cancer  screen-
ing — Columbia, Montour, Northumberland, Snyder 
and Union Counties, Pennsylvania. Consumer Health 
Profiles: Claritas, Inc; 2007.
13. Dempsey  AF,  Davis  MM.  Overcoming  barriers  to 
adherence to HPV vaccination recommendations. Am 
J Manag Care 2006;12(17 Suppl):S484-91.
14. Crosby  R,  Schoenberg  N,  Hopenhayn  C,  Melhan 
W.  Correlates  of  intention  to  be  vaccinated  against 
human  papillomavirus:  an  exploratory  study  of  col-
lege-aged women. Sex Health 2007;4(1):71-3.
15. Duval  B,  Gilca  V,  McNeil  S,  Dobson  S,  Money  D, 
Gemmill IM, et al. Vaccination against human pap-
illomavirus:  a  baseline  survey  of  Canadian  clini-
cians’  knowledge,  attitudes  and  beliefs.  Vaccine 
2007;25(45):7841-7.
16. Esposito S, Bosis S, Pelucchi C, Begliatti E, Rognoni 
A, Bellasio M, et al. Pediatrician knowledge and atti-
tudes regarding human papillomavirus disease and its 
prevention. Vaccine 2007;25(35):6437-46.
Appendix
Initial 1-page survey on human papillomavirus vaccine 
faxed to all primary care practices in the ACTION Health 
area (5 rural counties in Appalachian Pennsylvania)
Recently, there has been growing interest in the human papillomavirus 
(HPV) and its relation to cervical cancer. In 2006, the US Food and Drug 
Administration approved a vaccine to prevent cervical cancer caused by 
HPV. Gardasil, developed and produced by Merck Pharmaceuticals, pro-
tects against the  main types of HPV. Family planning centers and the 
Pennsylvania Department of Health have had numerous requests for the 
vaccine and information about the vaccine. Currently, the Pennsylvania 
Department of Health does not offer this vaccine. The ACTION Health 
Cancer Task Force is conducting a survey of all family practice centers, 
obstetricians/gynecologists, and pediatricians to determine the availability 
and present use of this vaccine. By conducting this survey, the Cancer Task 
Force hopes to offer educational programs to help better educate the public 
about HPV, cancer, and the vaccine. Thank you for completing this short 
survey.
1. Do you currently offer the HPV vaccine? (yes/no)
If yes:
Do you offer the vaccine to all females ages 9 to 26? (yes/no)
  If no, please explain.
Do you accept referrals for non-patients interested in receiving the 
vaccines? (yes/no)
How much do you charge for the vaccine for the uninsured or under-
insured?
If no:
Are you interested in offering this vaccine? (yes/no)
  If no, please explain.
Would you like more information about this vaccine? (yes/no)
2. Would you be willing to post flyers in your medical practice about 
HPV educational programs being offered by the ACTION Health 
Cancer Task Force? (yes/no)
. Please list any concerns, barriers, or comments you have about the 
HPV vaccine.
Follow-up survey to primary care practices that responded 
to the initial survey
Recently, there has been growing interest in the human papillomavirus 
(HPV) and its relation to cervical cancer. In December 2006, ACTION 
Health Cancer Task Force surveyed local family practice centers, obstetri-
cians/gynecologists, and pediatricians to see if the HPV vaccine was avail-
able, any insurance concerns, and any general concerns about this new 
vaccine. The response to the survey was wonderful; 8% of those surveyed 
responded. Because of the responses from the surveys we have been able 
to offer several education programs about HPV and cervical cancer. We are 
now asking you to please complete our follow-up survey. This short follow-
up will help us learn more about our counties’ response to the HPV vac-
cine. Thank you for completing this short survey.
1. Are patients requesting the vaccine for themselves or for their chil-
dren?
2. Are doctors and medical staff recommending the HPV vaccine to 
their patients? (yes/no)
If yes:
Do they recommend it for all females ages 9 to 26? (yes/no)
  If no, please explain.
. On average how many initial (first dose) HPV vaccines does your 
practice administer in a week?
. Are patients keeping their follow up appointments for the second and 
third dose? (yes/no)VOLUME 6: NO. 2
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. Do you administer mostly to girls ages 9 to 17 or women ages 18 to 
26?
6. Would you like more information about this vaccine? (yes/no)
7. Would any of the doctors or medical staff be interested in being a 
guest speaker for an educational program about HPV and cervical 
cancer? (yes/no)
8. Please list any concerns, barriers, or comments you have about the 
HPV vaccine.